Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01009840 · OUTCOME

Percent Change in IV Busulfan Dose

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients · Source last updated 2026-05-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Percent change
Interval / dispersion
Full Range
Time frame
Baseline (Day -12 to -9), Day -5

What was measured

The percent change in dose is relative to the busulfan dose administered at the Baseline Visit (Day -12 to -9) when a dose of 0.8 mg/kg was administered and on Day -5 when the Seattle Cancer Care Alliance recommended PK-adjusted dose was administered.

Analysis population: Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.

Groups in this outcome

IV Busulfan

Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IV Busulfan30

Reported measurements

Source class 1
Values in Percent change · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
IV Busulfan7.55Not reported-26.0047.50Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        -26.00
        upper Limit
        47.50
        value
        7.55
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
The percent change in dose is relative to the busulfan dose administered at the Baseline Visit (Day -12 to -9) when a dose of 0.8 mg/kg was administered and on Day -5 when the Seattle Cancer Care Alliance recommended PK-adjusted dose was administered.
dispersion Type
Full Range
groups
  1. description
    Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
    id
    OG000
    title
    IV Busulfan
param Type
MEDIAN
population Description
Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.
reporting Status
POSTED
time Frame
Baseline (Day -12 to -9), Day -5
title
Percent Change in IV Busulfan Dose
type
SECONDARY
unit Of Measure
Percent change

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice